CH488656A - Process for the production of new amines - Google Patents

Process for the production of new amines

Info

Publication number
CH488656A
CH488656A CH1583269A CH1583269A CH488656A CH 488656 A CH488656 A CH 488656A CH 1583269 A CH1583269 A CH 1583269A CH 1583269 A CH1583269 A CH 1583269A CH 488656 A CH488656 A CH 488656A
Authority
CH
Switzerland
Prior art keywords
hydroxy
isopropylamino
propane
salts
radical
Prior art date
Application number
CH1583269A
Other languages
German (de)
Inventor
Ulrich Dr Daeniker Hans
Karl Dr Schenker
Paul Dr Schmidt
Max Dr Wilhelm
Original Assignee
Ciba Geigy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CH1179964A external-priority patent/CH465640A/en
Application filed by Ciba Geigy filed Critical Ciba Geigy
Priority to CH1583269A priority Critical patent/CH488656A/en
Publication of CH488656A publication Critical patent/CH488656A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/24—Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

  

      Verfahren        zur    Herstellung neuer Amine    Gegenstand der Erfindung ist ein Verfahren zur  Herstellung der       1-Isopropylamino-2-hydroxy-3-(o-nieder-          alkoxymethyl-phenoxy)-propane     der Formel  
EMI0001.0004     
    worin R einen niederen Alkylrest, wie einen Äthyl-,  Propyl- oder Butylrest, vor allem aber den Methylrest  bedeutet, insbesondere also des     1-Isopropylamino-2-          hydroxy-3-(o-methoxymethyl-phenoxy)-propans,    und  ihrer Salze.  



  Die neuen Verbindungen, besonders das       1-Isopropylamino-2-hydroxy-3-(o-methoxymethyl-          phenoxy)-propan     oder das       1-Isopropylamino-2-hydroxy-3-(o-n-butoxymethyl-          phenoxy)-propan,     besitzen wertvolle pharmakologische Eigenschaften.     Ins-          b;:sondere    bewirken sie eine Hemmung adrenergischer  j-Rezeptoren. So hemmen sie z. B. an der mit Dial  narkotisierten Katze durch Isoproterenol hervorgerufene       Blutdrucksenkungen        in    Dosen von 0,01-1 mg/kg i. v.  Die Verbindungen können daher bei Herz- und Kreis  lauferkrankungen als Medikamente angewendet wer  den.  



  Das erfindungsgemässe Verfahren zur Herstellung  der neuen Verbindungen ist dadurch gekennzeichnet,  dass man in einem entsprechenden     1-Isopropylamino-2-          hydroxy-3-(o-niederalkoxymethyl-phenoxy)-propan,    das  am Stickstoffatom einen durch Hydrolyse oder     Hydro-          genolyse    abspaltbaren Rest aufweist, diesen Rest durch  Hydrolyse oder Hydrogenolyse abspaltet.    Durch Hydrolyse oder Hydrogenolyse abspaltbare  Reste sind z. B. a-Aralkylreste, wie Benzylreste,     Oxy-          carbonylreste,    wie a-Aralkoxycarbonylreste, z.

   B.     Car-          bobenzoxyreste,    oder Carbalkoxyreste, wie tert.     Butyl-          oxycarbonylreste,    oder Acylreste von Carbonsäuren,  z. B. niedere Alkanoylreste, wie der Acetylrest.  



  Die Hydrolyse und Hydrogenolyse können in übli  cher Weise, letztere besonders katalytisch, z. B. mit  Palladium-Tierkohle, Platinoxyd oder Raney-Nickel  vorgenommen werden. Die Hydrolyse einer Verbindung  der Formel a), worin X' für eine Alkylidengruppe steht,  wird vorzugsweise in saurer Lösung vorgenommen.  



  Je nach den     Verfahrensbedingungen    und Ausgangs  stoffen erhält man die Endstoffe in freier Form oder  in der ebenfalls in der Erfindung inbegriffenen Form  ihrer Salze. Die Salze der     Endstoffe    können in an sich  bekannter Weise, z. B. mit Alkalien oder     Ionenaustau-          schern,    in die freien Basen übergeführt werden.

   Von  den letzteren lassen sich durch Umsetzung mit orga  nischen oder anorganischen Säuren, insbesondere sol  chen, die zur Bildung von therapeutisch verwendbaren  Salzen geeignet sind, Salze     gewinnen.    Als solche Säuren  seien beispielsweise genannt: Halogenwasserstoffsäuren,  Schwefelsäuren, Phosphorsäuren, Salpetersäure, Per  chlorsäure, aliphatische, alicyclische, aromatische oder  heterocyclische Carbon- oder Sulfonsäuren, wie Amei  sen-, Essig-, Propion-, Bernstein-, Glykol-, Milch-,  Äpfel-, Wein-, Zitronen-, Ascorbin-, Malein-,     Hydroxy-          malein-    oder Brenztraubensäure;

   Phenylessig-, Benzoe-,  p-Amino-benzoe-, Anthranil-, p-Hydroxy-benzoe-,     Sali-          cyl-    oder p-Amino-salicylsäure, Embonsäure,     Methan-          sulfon-,    Äthansulfon-, Hydroxyäthansulfon-,     Äthylen-          sulfonsäure;    Halogenbenzolsulfon-, Toluolsulfon-,     Naph-          thalinsulfonsäure    oder Sulfanilsäure; Methionin,     Trypto-          phan,        Lysin    oder     Arginin.     



  Diese oder andere Salze der neuen Verbindungen,  wie z. B. die     Pikrate,    können auch zur     Reinigung    der  erhaltenen freien Basen dienen, indem man die freien  Basen in Salze überführt, diese abtrennt und aus     den              Salzen        wiederum    die Basen freimacht. Infolge der engen  Beziehungen     zwischen    den neuen Verbindungen in  freier     Form    und in Form ihrer Salze sind im voraus  gegangenen und nachfolgend unter den freien     Basen     sinn- und zweckmässig gegebenenfalls auch die entspre  chenden     Salze    zu verstehen.  



  Die neuen Verbindungen können als Racemate oder  in Form der Antipoden vorliegen. Das Racemat lässt  sich in üblicher Weise in die Antipoden zerlegen.  



  Die neuen Verbindungen können z. B. in Form  pharmazeutischer Präparate Verwendung finden, welche  sie in freier Form oder gegebenenfalls in Form ihrer  Salze in Mischung mit einem für die enterale oder  parenterale Applikation geeigneten pharmazeutischen  organischen oder anorganischen, festen oder flüssigen  Trägermaterial enthalten.  



  Die Ausgangsstoffe sind bekannt oder können, falls  sie neu sind, nach an sich bekannten Methoden erhalten  werden.  



  Verbindungen, die am Stickstoffatom einen durch  Hydrolyse oder Hydrogenolyse abspaltbaren Rest auf  weisen, erhält man z. B. durch Kondensation einer  Verbindung der Formel  
EMI0002.0006     
    oder einer Verbindung der Formel  
EMI0002.0007     
    mit einer Verbindung der Formel  
EMI0002.0008     
    worin R die oben gegebene Bedeutung besitzt, und bei  der Kondensation von Verbindungen b) und d) einer  der Reste X, und Y, für eine reaktionsfähig veresterte  Hydroxylgruppe steht und der andere eine     Amino-          gruppe    bedeutet, die durch einen abspaltbaren Rest  substituiert ist, und bei der Kondensation von Verbin  dungen c) und d) Y, eine durch einen abspaltbaren  Rest substituierte Aminogruppe bedeutet.  



  Reaktionsfähig veresterte Hydroxylgruppen sind ins  besondere solche, die mit einer starken organischen  oder anorganischen Säure, wie vor allem einer Halogen  wasserstoffsäure, z. B. der Chlor-, Brom- oder     Jodwas-          serstoffsäure,    oder einer Sulfonsäure, wie einer     Aryl-          sulfonsäure,    z, B. der p-Toluolsulfonsäure verestert sind.  



  Ferner sind diese am Stickstoff substituierten Ver  bindungen auch dadurch erhältlich, dass man ein     o-(Nie-          deralkoxymethyl)-phenol    oder ein Salz davon mit einer  Verbindung der Formel  
EMI0002.0017     
    oder  
EMI0002.0018     
    umsetzt, worin X eine reaktionsfähig veresterte Hy  droxylgruppe und X., ein durch Hydrolyse oder     Hydro-          genolyse    abspaltbarer Rest ist.  



  Im folgenden Beispiel sind die Temperaturen in  Celsiusgraden angegeben.    <I>Beispiel</I>  10,0g N-Acetyl-1-isopropylamino-2-hydroxy-3     -          (o-methoxymethyl-phenoxy)-propan    werden in 100 ml  Äthanol gelöst. Nach Zugabe von 25 ml 5-n     Salzsäure     erhitzt man 3 Stunden unter Rückfloss und dampft  anschliessend im Vakuum ein. Der Rückstand     wird    in  Wasser gelöst und durch Zugabe von 2-n Natronlauge  alkalisch gemacht. Es kristallisiert das       1-Isopropylamino-2-hydroxy-3-(o-methoxymethyl-          phenoxy)-propan     der Formel  
EMI0002.0027     
    das nach Umkristallisation aus Petroläther und Subli  mation bei 49-511 schmilzt.  



  Auf analoge Weise kann man das       1-Isopropylamino-2-hydroxy-3-(o-n-butoxymethyl-          phenoxy)-propan     herstellen, das bei     130-135 /0,02    mm destilliert und  bei 40-45  schmilzt.



      Process for the preparation of new amines The invention relates to a process for the preparation of the 1-isopropylamino-2-hydroxy-3- (o-lower-alkoxymethyl-phenoxy) propanes of the formula
EMI0001.0004
    where R is a lower alkyl radical, such as an ethyl, propyl or butyl radical, but above all the methyl radical, in particular of 1-isopropylamino-2-hydroxy-3- (o-methoxymethylphenoxy) propane and their salts.



  The new compounds, especially 1-isopropylamino-2-hydroxy-3- (o-methoxymethylphenoxy) propane or 1-isopropylamino-2-hydroxy-3- (on-butoxymethylphenoxy) propane, have valuable pharmacological properties Characteristics. In particular, they cause an inhibition of adrenergic j receptors. So they inhibit z. B. in the cat anesthetized with Dial caused by isoproterenol decreases in blood pressure in doses of 0.01-1 mg / kg i. v. The compounds can therefore be used as drugs for heart and circulatory diseases.



  The process according to the invention for preparing the new compounds is characterized in that a corresponding 1-isopropylamino-2-hydroxy-3- (o-lower alkoxymethyl-phenoxy) propane which has a residue on the nitrogen atom which can be split off by hydrolysis or hydrogenolysis , splits off this residue by hydrolysis or hydrogenolysis. Residues which can be split off by hydrolysis or hydrogenolysis are z. B. a-aralkyl, such as benzyl, oxy carbonyl, such as a-aralkoxycarbonyl, z.

   B. carbobenzoxy radicals, or carbalkoxy radicals, such as tert. Butyl oxycarbonyl radicals, or acyl radicals of carboxylic acids, eg. B. lower alkanoyl radicals, such as the acetyl radical.



  The hydrolysis and hydrogenolysis can in übli cher way, the latter particularly catalytically, for. B. be made with palladium charcoal, platinum oxide or Raney nickel. The hydrolysis of a compound of the formula a) in which X 'is an alkylidene group is preferably carried out in acidic solution.



  Depending on the process conditions and starting materials, the end products are obtained in free form or in the form of their salts, which is also included in the invention. The salts of the end products can in a conventional manner, for. B. with alkalis or ion exchangers, are converted into the free bases.

   Of the latter, salts can be obtained by reaction with organic or inorganic acids, in particular those which are suitable for the formation of therapeutically useful salts. Examples of such acids are: hydrohalic acids, sulfuric acids, phosphoric acids, nitric acid, perchloric acid, aliphatic, alicyclic, aromatic or heterocyclic carboxylic or sulfonic acids, such as formic, acetic, propionic, succinic, glycolic, lactic, Malic, tartaric, citric, ascorbic, maleic, hydroxy-maleic or pyruvic acid;

   Phenylacetic, benzoic, p-amino-benzoic, anthranil, p-hydroxy-benzoic, salicylic or p-amino-salicylic acid, emboxylic acid, methanesulphonic, ethanesulphonic, hydroxyethanesulphonic, ethylene sulphonic acid ; Halobenzenesulphonic, toluenesulphonic, naphthalenesulphonic acid or sulphanilic acid; Methionine, tryptophan, lysine or arginine.



  These or other salts of the new compounds, such as. B. the picrates, can also be used to purify the free bases obtained by converting the free bases into salts, separating them and in turn frees the bases from the salts. As a result of the close relationships between the new compounds in free form and in the form of their salts, the free bases in the preceding and in the following are meaningfully and appropriately also the corresponding salts.



  The new compounds can exist as racemates or in the form of the antipodes. The racemate can be broken down into the antipodes in the usual way.



  The new connections can e.g. B. in the form of pharmaceutical preparations are used which they contain in free form or optionally in the form of their salts in a mixture with a pharmaceutical organic or inorganic, solid or liquid carrier material suitable for enteral or parenteral administration.



  The starting materials are known or, if they are new, can be obtained by methods known per se.



  Compounds that have a residue on the nitrogen atom that can be split off by hydrolysis or hydrogenolysis are obtained, for. B. by condensation of a compound of the formula
EMI0002.0006
    or a compound of the formula
EMI0002.0007
    with a compound of the formula
EMI0002.0008
    in which R has the meaning given above, and in the condensation of compounds b) and d) one of the radicals X and Y stands for a reactive esterified hydroxyl group and the other is an amino group which is substituted by a removable radical, and in the condensation of compounds c) and d) Y is an amino group substituted by a residue which can be split off.



  Reactively esterified hydroxyl groups are in particular those that react with a strong organic or inorganic acid, such as a halogenated hydrochloric acid, eg. B. the chlorine, bromine or hydroiodic acid, or a sulfonic acid, such as an aryl sulfonic acid, for example p-toluenesulfonic acid are esterified.



  In addition, these compounds substituted on the nitrogen can also be obtained by mixing an o- (lower alkoxymethyl) phenol or a salt thereof with a compound of the formula
EMI0002.0017
    or
EMI0002.0018
    converts, in which X is a reactive esterified hydroxyl group and X. is a radical which can be split off by hydrolysis or hydrogenolysis.



  In the following example the temperatures are given in degrees Celsius. <I> Example </I> 10.0 g of N-acetyl-1-isopropylamino-2-hydroxy-3 - (o-methoxymethyl-phenoxy) -propane are dissolved in 100 ml of ethanol. After adding 25 ml of 5N hydrochloric acid, the mixture is heated under reflux for 3 hours and then evaporated in vacuo. The residue is dissolved in water and made alkaline by adding 2N sodium hydroxide solution. The 1-isopropylamino-2-hydroxy-3- (o-methoxymethylphenoxy) propane of the formula crystallizes
EMI0002.0027
    which melts after recrystallization from petroleum ether and sublimation at 49-511.



  1-Isopropylamino-2-hydroxy-3- (o-n-butoxymethylphenoxy) propane, which distills at 130-135 / 0.02 mm and melts at 40-45, can be prepared in an analogous manner.

Claims (1)

PATENTANSPRUCH Verfahren zur Herstellung der 1-Isopropylamino-2- hydroxy-3-(o-niederalkoxymethyl-phenoxy)-propane der Formel EMI0002.0033 worin R ein niederer Alkylrest ist, und ihrer Salze, dadurch gekennzeichnet, dass man in einem entspre chenden 1-Isopropylamino-2-hydroxy-3-(o-niederalkoxy- methyl-phenoxy)-propan, das am Stickstoffatom einen durch Hydrolyse oder Hydrogenolyse abspaltbaren Rest aufweist, diesen Rest durch Hydrolyse oder Hydro- genolyse abspaltet. UNTERANSPRÜCHE 1. PATENT CLAIM Process for the preparation of the 1-isopropylamino-2-hydroxy-3- (o-lower alkoxymethyl-phenoxy) -propane of the formula EMI0002.0033 wherein R is a lower alkyl radical, and its salts, characterized in that one in a corre sponding 1-isopropylamino-2-hydroxy-3- (o-lower alkoxymethyl-phenoxy) propane, the one on the nitrogen atom by hydrolysis or hydrogenolysis Has cleavable residue, this residue splits off by hydrolysis or hydrogenolysis. SUBCLAIMS 1. Verfahren nach Patentanspruch, dadurch gekenn zeichnet, dass man ein 1-Isopropylamino-2-hydroxy-3- (o-niederalkoxymethyl-phenoxy)-propan, das am Stick stoff einen a-Arylalkylrest enthält, hydrogenolysiert. 2. Verfahren nach Patentanspruch, dadurch gekenn zeichnet, dass man in einem 1-Isopropylamino-2-hydr- oxy-3-(o-niederalkoxymeth),l-phenoxy)-propan, das am Stickstoff einen Acylrest enthält, diesen abhydrolysiert. 3. Verfahren nach Patentanspruch oder Unteran spruch 1 oder 2, dadurch gekennzeichnet, dass man von Ausgangsstoffen ausgeht, in denen R der Methyl rest ist. 4. Process according to claim, characterized in that a 1-isopropylamino-2-hydroxy-3- (o-lower alkoxymethyl-phenoxy) propane which contains an α-arylalkyl radical on the nitrogen is hydrogenolyzed. 2. The method according to claim, characterized in that in a 1-isopropylamino-2-hydroxy-3- (o-lower alkoxymeth), l-phenoxy) propane which contains an acyl radical on the nitrogen, this is hydrolyzed. 3. The method according to claim or sub-claim 1 or 2, characterized in that starting materials are used in which R is the methyl radical. 4th Verfahren nach Patentanspruch oder Unteran spruch 1 oder 2, dadurch gekennzeichnet, dass man von Ausgangsstoffen ausgeht, in denen R der n-Butyl- rest ist. 5. Verfahren nach Patentanspruch oder Unteran spruch 1 oder 2, dadurch gekennzeichnet, dass man erhaltene Salze in die freien Basen umwandelt. 6. Verfahren nach Patentanspruch oder Unteran spruch 1 oder 2, dadurch gekennzeichnet, dass man erhaltene freie Basen in die Salze umwandelt. Process according to claim 1 or claim 2, characterized in that starting materials are used in which R is the n-butyl radical. 5. The method according to claim or sub-claim 1 or 2, characterized in that the salts obtained are converted into the free bases. 6. The method according to claim or sub-claim 1 or 2, characterized in that the free bases obtained are converted into the salts.
CH1583269A 1964-09-10 1965-07-09 Process for the production of new amines CH488656A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CH1583269A CH488656A (en) 1964-09-10 1965-07-09 Process for the production of new amines

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CH1179964A CH465640A (en) 1964-09-10 1964-09-10 Process for the production of new amines
CH1114467A CH477400A (en) 1964-09-10 1964-09-10 Process for the production of new amines
CH962865A CH485659A (en) 1964-09-10 1965-07-09 Process for the production of new amines
CH1583269A CH488656A (en) 1964-09-10 1965-07-09 Process for the production of new amines

Publications (1)

Publication Number Publication Date
CH488656A true CH488656A (en) 1970-04-15

Family

ID=27429233

Family Applications (1)

Application Number Title Priority Date Filing Date
CH1583269A CH488656A (en) 1964-09-10 1965-07-09 Process for the production of new amines

Country Status (1)

Country Link
CH (1) CH488656A (en)

Similar Documents

Publication Publication Date Title
DE965036C (en) Process for the preparation of p-(bis-2-chloroethylamino)-ª‰-phenyl-alanine
DE2351281B2 (en) Aminophenylethanolamine derivatives, their production and use
CH488656A (en) Process for the production of new amines
CH488657A (en) Process for the production of new amines
DE1131665B (en) Process for the preparation of aminosteroid compounds
DE662066C (en) Process for the preparation of substituted amides of fatty aromatic monocarboxylic acids
DE1595965A1 (en) Process for the preparation of 1,2,3,6,7,11b-hexahydro-4H-pyrazino- [2,1-a] -isoquinoline
CH481873A (en) Process for the preparation of a new amine
DE2530768C3 (en) PhenoxyaUcylaminpyridyläther, process for their production and pharmaceutical preparations containing them
CH465642A (en) Process for the production of new amines
CH490324A (en) Process for the preparation of a new amine
DE2403682C3 (en) S-methyl-Z-phenyl-S-benzothiazole n-acylic acid compounds and process for their preparation
CH489466A (en) Process for the preparation of a new amine
CH476678A (en) Process for the production of new unsaturated amines
AT269121B (en) Process for the preparation of new 1-isopropylamino-2-hydroxy-3- [o- (R-alk-O) -phenoxy] -propanes and their salts
AT361933B (en) METHOD FOR PRODUCING NEW 5,11- DIHYDRO-6H-PYRIDO (2,3-B) (1,4) - BENZODIAZEPINE-6-ON DERIVATIVES AND THEIR SALTS
CH475191A (en) Process for the production of new unsaturated amines
AT264500B (en) Process for the preparation of the new 1-isopropylamino-2-hydroxy-3- (o-allyloxyphenoxy) propane and its salts
AT266080B (en) Process for the preparation of the new 1-isopropylamino-2-hydroxy-3- (o-lower alkoxymethyl-phenoxy) -propanes and their salts
DE528270C (en) Process for the preparation of ephedrine derivatives
DE2246428C3 (en)
DE1543744C3 (en) 3-Alkylflavanones and processes for their preparation and pharmaceuticals containing them
CH498803A (en) 1-bopropyl amino 2-hydroxy-3-(2&#39; isopropoxy - phenoxy) propane and salts with phareological
DE1049868B (en) Process for the production of locally anesthetically effective anilides
CH474475A (en) Process for the production of new unsaturated amines

Legal Events

Date Code Title Description
PL Patent ceased